CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013		Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
Total revenue, net	$ 229,719	$ 213,246	[1]	$ 676,129	$ 615,445	[1]
Costs and expenses:
Cost of goods sold	85,974	81,767	[1]	255,333	243,208	[1]
Research and development	13,127	13,052	[1]	39,439	37,577	[1]
Selling, general and administrative	109,896	99,794	[1]	333,487	306,037	[1]
Intangible asset amortization	2,995	3,036	[1]	9,013	9,660	[1]
Goodwill, Impairment Loss	0	46,738		0	46,738
Total costs and expenses	211,992	244,387	[1]	637,272	643,220	[1]
Operating income (loss)	17,727	(31,141)	[1]	38,857	(27,775)	[1]
Interest income	25	38	[1]	145	390	[1]
Interest expense	(5,916)	(5,316)	[1]	(16,440)	(15,081)	[1]
Other income (expense), net	(293)	(263)	[1]	142	(1,544)	[1]
Income (loss) before income taxes	11,543	(36,682)	[1]	22,704	(44,010)	[1]
Income tax expense (benefit)	1,736	(6,352)	[1]	5,866	(9,172)	[1]
Net income (loss)	9,807	(30,330)	[1]	16,838	(34,838)	[1]
Basic net income per common share (in dollars per share)	$ 0.30	$ (1.09)	[1]	$ 0.52	$ (1.25)	[1]
Diluted net income per common share (in dollars per share)	$ 0.30	$ (1.09)	[1]	$ 0.51	$ (1.25)	[1]
Weighted average common shares outstanding (See Note 10):
Basic (in shares)	32,450	27,896	[1]	32,374	27,855	[1]
Diluted (in shares)	32,906	27,896	[1]	32,844	27,855	[1]
Comprehensive income (loss) (See Note 11)	$ (6,364)	$ (21,640)	[1]	$ 1,593	$ (30,754)	[1]

[1] See Note 1 of these condensed consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.